OPINION: 2025 was a difficult year for ITV, with the broadcaster suffering cuts across its daytime and soap offerings - but there's more at risk.

Inside View: Ignore the haters pushing a revisionist history, and recognize the American experiment for the success that it is. Photo: Michael Brochstein/Zuma Press Grand Rapids, Mich. As the U.S.

The end of the 60s was a transitional time in America – not least for the members of Creedence Clearwater Revival. And so, shrugging off the backslaps, a steely-eyed Fogerty sat down to write the band ...

In a cavernous 19th-century textile mill building in Fall River, Massachusetts, expert artisans stitch together thick leather motorcycle jackets worn by celebrities and racing stars. Across town in a ...

Click to share on Facebook (Opens in new window) Facebook Click to share on X (Opens in new window) X After playing J.D. in the original series, Braff is confirmed to return as one of the leads in the ...

Netflix is officially taking audiences back to Hillman College. The streamer has announced a series order for A Different World, a fresh sequel to the beloved 1990s sitcom that helped define a ...

With cable television being dwarfed by the streaming world these days, it should come as no surprise that some series that once arrived on Cartoon Network have found new life on other platforms.

At least Erika Kirk’s widely promoted December 13 appearance with Bari Weiss on CBS News raised one timely question: What did we just watch? I could be alone in wondering. The audience for the town ...

This image shows a still from the film “The Testament of Ann Lee.” (Credit: Searchlight Pictures via AP.) Listen LOS ANGELES — At the movies this fall, Josh O’Connor plays a hot priest with a ...

Genentech, a member of the Roche Group, said the U.S. Food and Drug Administration approved its treatment for follicular lymphoma. The therapy, Lunsumio VELO, can be used to treat adult patients with ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio amid competition among CD20xCD3 bispecific antibodies. The FDA has approved ...